In Segment C, individuals will obtain ABBV-744 and oral navitoclax. In Segment D, individuals will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until sickness progression or maybe the contributors are not able to tolerate the study drugs. There may be greater treatment burden for individuals In this https://ricardozlwhu.ambien-blog.com/38259907/indicators-on-clinical-trial-recruitment-for-abbv-744-study-you-should-know